VOLUME 24 NUMBER 12 DECEMBER 2017 nature structural & molecular biology a r t i c l e s N-linked protein glycosylation is one of the most abundant posttranslational modifications of proteins that is present in all domains of life [1] [2] [3] [4] . It is essential in eukaryotes, facilitating many biological processes such as protein folding, quality control, and host-pathogen interactions [5] [6] [7] , and influences virulence in bacteria 8, 9 . The molecular mechanism of the glycan transfer from LLO to the acceptor asparagine located in glycosylation sequons N-X-(S/T) is conserved 10,11 and catalyzed by the membrane-integral OST. OST is a member of the C family of glycosyltransferases, which consists of membrane proteins that are located in the endoplasmic reticulum or the plasma membrane and that contain 8-13 predicted transmembrane helices 12, 13 . OST of higher eukaryotes is a multiprotein complex with STT3 as a catalytic subunit. In contrast, archaea, kinetoplastids and some proteobacteria contain single-subunit OST enzymes that are homologous to STT3 (refs. 7, [14] [15] [16] . Eukaryotic and bacterial LLOs differ in the length and configuration of the polyprenyl tail and in the nature of the attached glycans. However, all LLOs contain pyrophosphate or phosphate moieties that serve as the leaving groups of the nucleophilic substitution reaction 1, 3, 10 .
studied using a Dab-containing peptide. We therefore synthesized various LLO analogs (Fig. 1a) with the goal of identifying a useful compound for structural studies. It was previously shown that watersoluble monosaccharide-containing LLOs can serve as substrates for PglB 25 . We followed a similar synthetic approach and generated LLO analogs containing one N-acetyl-D-glucosamine (GlcNAc) moiety, a pyrophosphate group, and polyprenyl tails of different lengths in either cis or trans configuration.
To determine the rates and Michaelis-Menten constants of the synthetic LLOs, we used a fluorescently labeled peptide carrying the glycosylation sequon to monitor the glycosylation reaction by in-gel fluorescence 20 . Although it has previously been suggested that at least four isoprenyl units are required for PglB activity 25 , we found that compounds with as few as two isoprenyl units allowed the glycosylation reaction to proceed, albeit with lower rates ( Supplementary  Fig. 1 ). We tested two compounds that contained three or four isoprenyl units in trans configuration, (ωEE)-PP-GlcNAc (or farnesyl-PPGlcNAc) and (ωEEE)-PP-GlcNAc (or geranylgeranyl-PP-GlcNAc), and one compound containing four isoprenyl units in cis configuration, (ωZZZ)-PP-GlcNAc (or nerylneryl-PP-GlcNAc). The latter recapitulates the stereochemistry of the wild-type LLO lipid moiety ( Supplementary Fig. 2a ). Although all synthetic LLO analogs were recognized as substrates by PglB, their turnover rates ( Table 1 and Fig. 1b) were considerably lower than the rate we observed with fulllength C. jejuni heptasaccharide LLO (wild-type LLO) of 1.55 ± 0.32 peptides per second (error denotes s.d. of six independent cell cultures, n = 6). Intriguingly, whereas the K M of the (ωEE)-PP-GlcNAc compound was six-fold higher than that of the (ωEEE)-PP-GlcNAc compound, the turnover rate was only two-fold lower ( Table 1 and Supplementary Fig. 3 ). This finding suggests that while longer polyprenyl tails indeed increase the affinity of LLO analogs for PglB, the steps following LLO binding also determine the rate of the reaction. Although the stereochemistry of the double bonds of polyprenyl tail had no impact on LLO affinity (unaltered K M values), it affected the turnover rates ( Table 1, Fig. 1b and Supplementary Fig. 3 ), thus indicating an impact on the transfer reaction. Similar specificity was observed for the O-OST PglL from Neisseria meningitides, of which the stereochemistry of the lipid carrier strongly influenced the glycosylation reaction 26 . We identified (ωZZZ)-PP-GlcNAc as a PglB substrate that has a high turnover rate (Fig. 1b) while also having sufficiently high solubility for cocrystallization experiments.
This compound then served as a template for the design of nonreactive LLOs. It has been shown that nonhydrolyzable substrate analogs act as inhibitors rather than donors for glycosyltransferases that use nucleotide-activated 27 or lipid-linked glycans 28 . Partly following earlier procedures [28] [29] [30] , three nonhydrolyzable LLOs were synthesized, (ωZZZ)-PPS-GlcNAc, (ωZZZ)-PPC-GlcNAc and (ωZZZ)-PPC(OH)-GlcNAc, which contained unreactive thiophosphate, phosphonate, or hydroxyphosphonate groups, respectively, replacing the first phosphate group connected to the anomeric C1 atom of the reducing-end GlcNAc. The GlcNAc phosphonate 29 (Fig. 1c, 1) , GlcNAc hydroxyphosphonate 29 (Fig. 1c, 2) and GlcNAc thiophosphate 31, 32 ( Fig. 1c, 3) were individually coupled to nerylneryl phosphate 25 ( Fig. 1c, 4 ) using 1,1′-carbonyldiimidazole (CDI), then deacetylated with NH 4 OH and purified on basified silica gel 28 . Apparent IC 50 of these compounds were determined in PglB-catalyzed glycosylation containing (ωZZZ)-PP-GlcNAc as the functional LLO (Fig. 1d) . The results showed similar inhibitory potencies for the phosphonate-and hydroxyphosphonate-containing LLO analogs, but a lower potency (higher IC 50 value) for the thiophosphate-containing analog ( Table 2) . All IC 50 values were considerably higher than the K M value of the corresponding, functionally active (ωZZZ)-PP-GlcNAc) compound, suggesting that the oxygen atom of the natural pyrophosphate moiety directly or indirectly (for example, due to a different bond angle or bond length 33 ) contributes to LLO binding. 
Structure of the ternary complex and peptide-binding pocket
We cocrystallized a sequence-optimized variant of C. lari PglB with the hexapeptide DQNATF and the synthetic, nonhydrolyzable LLO analog (ωZZZ)-PPC-GlcNAc (Supplementary Fig. 2b ) and determined its structure at 2.7-Å resolution ( Table 3 and Fig. 2a) . The PglB construct contained several amino acid changes introduced with the aim of improving lattice contacts (details in Online Methods). The construct exhibited an increased thermostability (data not shown) and was less prone to aggregation, but its in vitro glycosylation activity was indistinguishable from the turnover rate of 1.50 ± 0.04 peptides per second determined previously for wild-type PglB 20 . The architecture of PglB is similar to the previously determined peptide-bound PglB structure 17 , in which the C-terminal fragment of EL5 (C-EL5, located between transmembrane helices TM9 and TM10a) pins the bound acceptor peptide against the periplasmic domain of PglB. However, we found that the previously disordered, N-terminal segment of the external loop EL5 (N-EL5) now adopts a defined 3D conformation, folding over and significantly contributing to the binding of LLO (Fig. 2a and Supplementary Figs. 4 and 5) . Notably, N-EL5 forms an α-helix located at the membrane boundary, with the helix axis forming an angle of ~30° relative to the membrane plane. A similar helix was observed in one of the apo structures of AglB 18 , suggesting that N-EL5 has a propensity for forming this secondary structure element. However, this formation of a helix is functionally relevant only upon LLO binding.
High-quality electron density was found for both substrates (Fig. 2b,c) , which are bound on opposite sides of the tunnel connecting the active site of PglB, indicated by the catalytic Mn 2+ ion, to the peptide-binding pocket. The location of bound peptide in the ternary complex structure is unaltered relative to that of the peptide-only structure 17 , with the side chain of the acceptor asparagine located in a tunnel formed between C-EL5 and the core of PglB (Fig. 2b) . The carboxamide group of the acceptor asparagine is in proximity to the catalytically essential residues D56 and E319, as well as the catalytic Mn 2+ ion (Supplementary Fig. 6a ). Although the exact rotamer of the carboxamide group of the acceptor asparagine side chain cannot be defined, we found continuous electron density to the nearby D56 residue (but not to E319), suggesting a strong contact in the form of a hydrogen bond. No bound water was identified near the carboxamide group of the acceptor asparagine, but three water molecules were placed near the Mn 2+ ion. Combined with the contacts to the conserved residues D56, E319 and D154, the contacts to the water molecules generate a distorted octahedral coordination of the metal( Supplementary  Fig. 6b) . Importantly, the nitrogen atom of the acceptor asparagine side chain is approximately 6 Å apart from the C1 atom of the reducing-end GlcNAc of the LLO analog (Fig. 2b) , suggesting that in order for the transition state of the reaction to be reached, further closing of the distance is required.
Our structure reveals that a short loop containing the DGGK [ 481 DGGK] motif that is conserved in many bacteria is present near the active site and interacts both with bound peptide and with the LLO molecule (Fig. 2b,c) . The backbone carbonyl of G482 forms a hydrogen bond with the amide nitrogen of the acceptor asparagine (2.9-Å distance), but not with the GlcNAc moiety of the LLO. The closest contact between the DGGK motif and the GlcNAc moiety of the LLO is formed by two backbone atoms (N and Cα) of G483, with a distance of 3.8 Å, representing weak van der Waals interactions. The side chains of D481 and K484 point away from the substrates and are engaged in salt bridges with residues from the periplasmic domain Figure 1d . Errors denote s.d. of four independent protein preparations (n ≥ 4).
a r t i c l e s and therefore probably have structural roles. The DGGK loop had previously been investigated and found to be essential for the function of C. jejuni PglB 34, 35 . Given the proximity of this loop to the reducing-end GlcNAc of the bound LLO analog, it is likely to impose steric constraints during the transfer reaction.
LLO-binding site and interactions with PglB
The density for the synthetic (ωZZZ)-PPC-GlcNAc molecule was of excellent quality, allowing unambiguous building of its structure (Fig. 2c) . The polyprenyl tail reaches approximately halfway across the membrane ( Fig. 3a) and has largely defined conformation. It is tightly embedded in a hydrophobic groove of the transmembrane domain of PglB but also forms van der Waals contacts with hydrophobic residues on N-EL5 located ~4 Å away. Our finding that electron density of the entire nerylneryl tail was resolved suggests that at least four isoprenyl units contribute to the binding of wild-type LLO to PglB. The pyrophosphate and GlcNAc moieties are bound in the active site, near the Mn 2+ ion. However, there is no direct contact between the pyrophosphate oxygens and the metal ion, as the shortest distance is ~5 Å. Instead, the phosphate connected to GlcNAc forms a salt bridge with R375, a conserved residue whose essential role was previously reported 20 . The second phosphate group (connected to the polyprenyl tail) forms multiple hydrogen bonds, one of which is with Y293, a residue from N-EL5 that was previously identified as essential to PglB function. Intriguingly, the contacts between PglB and the pyrophosphate and GlcNAc moieties of the LLO are all of polar or electrostatic nature. The above interactions can explain why the previously identified R375 and Y293 residues are essential for the glycosylation activity of PglB, but not for sequon binding. A mutation of R375 to alanine had earlier been reported to abolish turnover of PglB, without affecting acceptor peptide binding 20 . In contrast, a R375K mutant had revealed only a moderate reduction in activity, in line with the functional importance of the salt bridge provided by this residue. Based on the functional analysis of Y293 mutants, we had earlier proposed that it might form a stacking interaction with the reducing-end sugar 36 . Our structure disproves this interpretation, clearly showing a hydrogen bond with a pyrophosphate oxygen. Whereas a Y293A mutation had been found to abolish PglB function, a Y293F mutation, despite being unable to form a hydrogen bond with the pyrophosphate moiety, retained some activity. This suggests that in addition to a direct contact with the LLO, the aromatic ring of Y293 has a structural role in stabilizing the conformation of EL5 when LLO is bound.
There are several additional residues interacting with the LLO. These include Y196, S198 and Q289, all of which form hydrogen bonds with the pyrophosphate moiety of LLO (Fig. 3b) . In addition, the hydroxyl group of Y468 forms a hydrogen bond to the N-acetyl substituent of the reducing-end GlcNAc moiety. Y468 is part of the extended WWD motif and is strictly conserved in OSTs that accept HexNAc reducing-end sugars and had therefore been proposed to provide interactions with the N-acetyl group 17 . To analyze the relevance of the interactions observed in the structure, we mutated the involved residues and determined turnover rates of PglB using both the fulllength wild-type LLO and the synthetic (ωZZZ)-PP-GlcNAc analog (Fig. 3c,d) . Mutations of Y468 and Y196 caused a strong reduction or complete loss of PglB activity, whereas mutations of Y79, S198 and Q289 did not affect the activity as strongly. The activity of a Y468A mutant was reduced by 1,000-fold using wild-type LLO and 600-fold using synthetic LLO. In contrast, the mutation Y468F showed only a r t i c l e s 50-fold and 2.3-fold reduction in turnover rate when using synthetic and wild-type LLO, respectively. This finding suggests that in addition to the hydrogen bond provided by the hydroxyl group, the aromatic ring of Y468 has a structural role in the active site. There was an intriguing difference in the impact of the mutations on PglB function with wild-type LLO versus the synthetic analog. The rates observed with the synthetic LLO analog were generally more strongly reduced, indicating that additional interactions exist between PglB and the glycan or undecaprenol moieties in the wild-type LLO.
Functional studies with disaccharide-containing LLO analogs Our structure reveals that both the C3 and C4 atoms of the GlcNAc moiety are exposed to the solvent and that nonreducing extensions with both α-1,3 and β-1,4 glycosidic linkages are compatible without steric clashes. To further explore the impact of additional saccharides on LLO binding and specificity, we used synthetic farnesyl-PP-chitobiose (containing a GlcNAc-β-1,4-GlcNAc glycan) 28 and chemoenzymatically generated farnesyl-PP-GlcNAc-α-1,3-GalNAc, which we produced from synthetic farnesyl-PP-GlcNAc using purified PglA protein 37, 38 (Fig. 4a) . We found that both disaccharide LLOs served as glycan donors for PglB, and the resulting glycopeptides containing two saccharides were indeed observed by tricine SDS-PAGE (Fig. 4b) .
Compared to those of farnesyl-PP-GlcNAc, the chemo-enzymatically extended farnesyl-PP-GlcNAc-α-1,3-GalNAc revealed a two-fold increase in turnover and a reduction of K M value by a factor of two (Table 1) . Intriguingly, whereas the K M of the chitobiose-containing analog was only twice that of farnesyl-PP-GlcNAc-α-1,3-GalNAc, the observed turnover rate was reduced ~300-fold ( Table 1 and Fig.  4c,d ). This suggests that although the α-1,3-linked second saccharide unit contributes little to the initial binding of LLO, it is compatible with the subsequent transfer reaction, whereas the chitobiose-containing LLO does not allow PglB to reach the transition state effectively, which could be due to steric clashes or missing interactions with the enzyme.
Immobilization of the external loop 5 by disulfide cross-linking
The structure reveals that in order to access the active site, the glycan of LLO diffusing to PglB in the lipid bilayer has to 'dive' under the external loop 5, which subsequently becomes ordered. We hypothesized that for efficient LLO binding, full disordering of at least the N-EL5 segment would have to occur. We therefore generated a mutant of PglB that contained two cysteines, one in N-EL5 (V294C) and another in the transmembrane domain of PglB (R371C). Upon addition of an oxidizing agent, a disulfide cross-link was formed, tethering N-EL5 to the transmembrane domain and restricting the opening for a glycan to thread under EL5 (Fig. 5a) . The cross-linking yield was determined to be 80 ± 2.9% (Supplementary Fig. 7 ). The in vitro activity of this PglB mutant was unaltered compared to that of the wild-type protein both for full-length, wild-type LLO and for the synthetic LLO analog nerylneryl-PP-GlcNAc (1.42 ± 0.12 peptides per second and 2.8 ± 0.7 peptides per minute, respectively, error denotes s.d. of three independent cell cultures and protein preparations, n = 3). However, upon disulfide cross-linking, a difference was evident. Whereas the cross-link did not affect the activity with the monosaccharide-containing LLO analog, the turnover observed for wild-type LLO was reduced 3.8-fold (Fig. 5b) . This suggests that LLO binding, a r t i c l e s including glycan passage through the loop EL5, was at least partially rate limiting.
DISCUSSION
Our results provide the first structural insight into a STT3 protein (and to the best of our knowledge any glycotransferase C-family member) with both the acceptor peptide and the lipid-linked donor substrates bound. We have captured PglB in an intermediate state, before glycan transfer from the LLO to the peptide. To reach its observed binding site, LLO has to be pulled out of the membrane. PglB facilitates this step by providing a hydrophobic groove that binds the polyprenyl chain and by providing several specific contacts to the hydrophilic moiety of the LLO, including a salt bridge from R375 to the pyrophosphate group. The distance between the atoms that would ultimately form an Nglycosidic bond (carboxamide nitrogen of the acceptor asparagine and C1 atom of the reducing-end sugar) is ~6 Å in our structure, a distance that is too long for the reaction to proceed. It is possible that the use of a phosphonate LLO analog for our structural studies might have contributed to the observed distance to the acceptor peptide, because phosphonates have a slightly different geometry than pyrophosphates (longer P-C than P-O bonds and slightly different bond angle), and the methylene group cannot form a strong contact with the Mn 2+ ion. However, these differences are small and cannot explain the gap that needs to be bridged to reach the transition state of the reaction. This requires a conformational change, during which the LLO probably has to shift toward the peptide, because the peptide is more firmly embedded in its binding site. LLO shifting would involve a repositioning of the pyrophosphate moiety, whereby the phosphate group currently in contact with the conserved R375 would replace water molecules and interact with the Mn 2+ ion, in agreement with the essential role of the metal ion for reactivity 12, 13, 20, 34, 39 . The second phosphate would then take the place of the first in forming a salt bridge with R375. Importantly, in our structure, steric clashes would prevent such a repositioning. In particular, the loop containing the DGGK motif blocks LLO from further approaching the acceptor asparagine. The importance of this motif for PglB function was previously recognized: in C. jejuni PglB, mutations of the aspartate side chain of the DGGK motif to alanine or glutamate significantly decreased glycosylation activity, although the effect was partially reversed when higher LLO concentrations were used 34 . Molecular dynamics simulations implicated the motif in correctly orienting the carboxamide group of the acceptor asparagine residue 40 . However, beyond the requirement for a conformational change to allow the acceptor asparagine and the LLO to approach, the exact role of the motif cannot be defined at present. Our results also cannot clarify the exact mechanism of asparagine carboxamide group activation (the twisted amide hypothesis) further. Nevertheless, our results provide a promising starting point for computational approaches aimed at exploring the molecular events of the transfer step.
Our results also define the role of EL5, a loop that is present in all STT3 proteins and that has a dual function in binding peptide (C-EL5) and LLO (N-EL5). Because enzymatic cleavage of EL5 has been observed to result in only a slight reduction in activity 36 , the two functions of EL5 are independent of each other and thus modular. In contrast to recent molecular dynamics simulations that proposed that EL5 becomes disordered upon LLO binding 41 , our structural data demonstrate that the opposite is correct. Our disulfide cross-linking experiment also demonstrates that the larger the glycan moiety, the slower the diffusion of the donor LLO to the active site, given that the glycan must dive under or thread into EL5. This has consequences for the mechanism of PglB, as outlined in Figure 6 . In the absence of substrates (state 1), EL5 is flexible, disordered, and disengaged from the OST core. This matches one of the apo-AglB structures 18 . The binding of the substrates can in principle occur in either order. If peptide binds first (state 2), C-EL5 becomes ordered, as demonstrated by the peptide-only structure of PglB 17 . If LLO binds first (state 2′), N-EL5 might be engaged, but no structure of this state is currently available. Given that eukaryotic OST does not have a longer EL5 than bacterial PglB does, but eukaryotic LLO has a larger, more branched glycan, it is tempting to speculate that binding of LLO before the binding of peptide could be a more efficient mechanistic route for OST, because when both N-EL5 and C-EL5 are disengaged, the large glycan moiety can more easily access the active site.
Not only does the ternary complex structure of PglB provide a mechanistic understanding of bacterial OSTs, it also gives insight into structural changes that may be required for the function of all OSTs, as the glycosylation mechanism is thought to be broadly conserved in all domains of life. In addition, it provides opportunities for engineering the substrate specificity with respect to the LLO. This may be applied in the development and production of glycoconjugate therapeutics by inducing relaxed substrate specificity of PglB in order to synthesize various new bacterial and eukaryotic peptidoglycans to use as novel vaccines.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Figure 6 Glycosylation mechanism. PglB is shown as a gray molecular surface, with N-EL5 and C-EL5 in turquoise and purple, respectively. States are indicated with circled numbers. In state 1, no substrates are bound and EL5 is disordered, as indicated by a dashed line. Depending on whether LLO or peptide binds first, states 2 or 2′ are reached, respectively. Bound LLO is represented by a yellow line for isoprenoid moieties, yellow squares for N-acetyl-galactosamine (GalNAc), and blue circles for glucose (Glc). The pyrophosphate moiety is hidden behind N-EL5. State 2 is shown in a yellow-shaded box surrounded by dashed lines to indicate that no structure exists of this state. The ordering of N-EL5 in state 2 is putative. The observed crystal structure of the ternary complex reflects state 3, with acceptor peptide and LLO bound and the entire EL5 ordered.
ONLINE METHODS

Construction of plasmids.
A construct of PglB used in all experiments contained several amino acid changes generated to improve protein crystallization, including lattice contacts. The optimized construct was fully functional, less prone to aggregation and exhibited an increased thermostability compared to that of wildtype PglB (data not shown). Mutations in the pglB gene of C. lari were generated using the QuikChange method on the pSF2 plasmid 17 . The resulting cysteineless construct with removed glycosylation sites and carrying mutations: K2E, C17A, C30A, A108T, C360L, N535Q, Q536K, K549P, D550N, F553I, N556P, A600P,  A602D, T606K, T607Q, V610I, M611T, I619S, F622Y, A624S, V627I, A630N , F663Y, and F670Y was referred to as PglB. All subsequent mutations in the LLObinding site were based on this construct.
Overexpression and purification of PglB. Overexpression and purification of PglB and PglB mutants was performed as previously described 17 . Briefly, PglB was overexpressed in Escherichia coli BL21-Gold cells (DE3) (Strategene) at 37 °C in five-liter flasks using Terrific Broth medium supplemented with 1% glycerol (w/v). The cells were induced at 37 °C for 4 h at A 600 of 3.0 by adding 0.1% arabinose (w/v). Cells were harvested by centrifugation and cell pellets were stored at −80 °C. All following steps were carried out at 4 °C. Cells were resuspended in 25 mM Tris-HCl, pH 8.0, 250mM NaCl and disrupted in a M-110-l microfluidizer (Microfluidics) at 15,000 p.s.i. chamber pressure. Membranes were pelleted by centrifugation at 100,000g for 30 min and solubilized in 25 mM Tris-HCl, pH 8.0, 250 mM NaCl, 10% glycerol (v/v) and 1% N-dodecyl-β-D-maltopyranoside (w/v) (DDM, Anatrace) for 1.5 h. All subsequent purification buffers contained 0.016% DDM. PglB was purified on a nickel-nitrilotriacetic acid (Ni-NTA) Superflow affinity column (Qiagen) and desalted into 10 mM MES, pH 6.5, 100 mM NaCl, 3% glycerol (v/v), and 0.016% DDM. For crystallization experiments, desalted protein was concentrated to 6 mg mL −1 in an Amicon Ultra-15 concentrator (Milipore) with a molecular mass cutoff of 100 kDa and purified by size exclusion chromatography (Superdex 200 10/300, GE Healthcare) in desalting buffer. Collected fractions were pooled and concentrated to 12 mg mL −1 .
Purification of the PglB V294C R371C mutant. The PglB V294C R371C mutant was purified as described above with the addition of 10 mM β-mercaptoethanol to resuspension, solubilization, washing and elution buffers. The mutant was first desalted into 25 mM Tris-HCl, pH 8.0, 250 mM NaCl, 10% glycerol (v/v), 0.016% DDM supplemented with 1 mM CuCl 2 and incubated for 30 min at 4 °C, then desalted into 10 mM MES, pH 6.5, 100 mM NaCl, 3% glycerol (v/v), and 0.016% DDM. A small fraction of non-cross-linked V294C/R371C PglB was used as a control for quantification of the cross-linking efficiency and glycosylation activity. For glycosylation turnover measurements of the reduced V294C R371C PglB mutant, cross-linked samples were treated with 10mM DTT.
Quantification of cross-linking efficiency. The estimation of the cross-linking efficiency was performed by labeling free cysteines with fluorescein 5-maleimide. The cross-link and control sample were incubated with a ten-fold molar excess of fluorescein 5-maleimide over cysteines for 10 min at 4 °C. The reaction was quenched with 2 mM N-ethylmaleimide. The same amount (0.5 µg) of labeled samples was resolved by SDS-PAGE and fluorescent bands were visualized using the Typhoon Trio Plus imager (GE Healthcare). Band intensities were calculated in ImageJ.
Protein crystallization. Ac-DQNATF{p-NO 2 }-NH2, nerylneryl-PPC-GlcNAc and MnCl 2 were added to the concentrated protein to the final concentration of 0.75 mM, 2 mM, 1 mM, respectively and incubated for 15 min at 4 °C. PglB was crystallized by vapor diffusion in hanging drops at 20 °C against a reservoir containing 100 mM glycine, pH 9.4, 120 mM Li 2 SO 4 , and 29-31% PEG400 at the protein-to-reservoir ratio 2:1. Crystals usually appeared after 10-12 d and grew to full size within 3-4 weeks. Crystals were cryoprotected by stepwise addition of cryoprotectant PEG400 up to 30% final concentration and directly flash frozen in liquid nitrogen before data collection.
Data collection and structural determination. The X-ray data was collected at the microfocus X06SA beamline at the Swiss Light Source (Villigen). The wavelength for data collection was 0.9998 Å. All data were processed using XDS 42 . There was no indication of any severe diffraction anisotropy. The ternary complex crystallized in the P2 1 2 1 2 1 space group, containing one PglB molecule per asymmetric unit. The structure was solved by molecular replacement using peptideonly PglB (PDB 3RCE) as a model. The iterative model building and refinement was performed in Coot 43 and Phenix 44 . Final refinement statistics and data collection are summarized in C. jejuni wild-type LLO extraction. Extraction of the C. jejuni heptasaccharide wild-type LLO (WT LLO) was done as described previously 46 . Briefly, LLO was extracted from SCM6 E. coli cells carrying a C. jejuni pglB mut cluster, containing an inactivated pglB gene. LLO was extracted with a mixture of chloroform/ methanol/ water (10:10:3 v/v/v) and then rotary evaporated. The LLO was reconstituted in 10 mM MES, pH 6.5, 100 mM NaCl, 1% Triton X-100 (w/v) buffer, and its concentration was determined by titrating different amounts of LLO against constant amounts of fluorescently labeled peptide in an in vitro glycosylation assay (see below).
In vitro glycosylation assay. In vitro glycosylation assays were performed as described previously 20 , using a labeled acceptor peptide 5-carboxyfluorescein-GS-DQNATF-NH 2 (10 µM) as an acceptor substrate and wild-type LLO (50 µM) or nerylneryl-PP-GlcNAc (500 µM) as a donor substrate. Reaction mixtures with wild-type LLO and nerylneryl-PP-GlcNAc contained 1 nM or 100 nM PglB, respectively. 1% Triton X-100 (w/v) was added only to wild-type LLO reaction mixtures. For turnover-rate determination, a total of six samples were taken at different time intervals so that the reaction was in the linear range. Data was fitted by linear regression in GraphPad PRISM7.
Determination of the Michaelis-Menten constants.
Michaelis-Menten kinetics of the monosaccharide and disaccharide LLO analogs were determined using the in vitro glycosylation assay described above. 100 nM PglB was used for assays containing monosaccharide LLO analogs, whereas 1 µM PglB was used for assays containing disaccharide LLO analogs. The concentrations of LLO analogs varied from 1-1,000 µM. Samples were taken at different time points and initial turnover rates were calculated for each concentration of LLO analog using linear regression. The resulting rates were plotted against LLO concentration and the data was fitted by nonlinear regression using the Michaelis-Menten analysis tool in GraphPad PRISM7.
Determination of the apparent IC 50 values. Apparent IC 50 values of nonhydrolyzable LLO analogs were determined using the in vitro glycosylation assay described above. For the kinetics of inhibitory LLO analogs, reaction mixtures contained 17 µM nerylneryl-PP-GlcNAc and 10-5,000 µM of competitive LLO inhibitors. PglB was added at a final concentration of 100 nM to start the reaction. Samples were taken at different time points and initial turnover rates were calculated using linear regression. The resulting rates were plotted against the concentration of the inhibitory LLO and the data was fitted by nonlinear regression in GraphPad PRISM7.
Synthesis of LLO analogs. Six LLO substrate analogs were synthesized according to previously reported procedures with slight modifications 25, 28, 47 . Five of them were composed of a GlcNAc residue linked to polyprenyl pyrophosphates of different chain length and stereochemistry (E-geraniol, Z-nerol, E,E-farnesol, E,E,E-genanylgeraniol, and Z,Z,Z-nerylnerol), and the sixth had a chitobiose moiety coupled to E,E-farnesol. The synthetic strategy included three steps: the synthesis of GlcNAc or chitobiose α-phosphate, the preparation of the lipid phosphate precursors, and the coupling of both monophosphates to the desired final pyrophosphates. Nerylneryl-PP-GlcNAc ((ωZZZ)-PP-GlcNAc), geranylgeranyl-PP-GlcNAc ((ωEEE)-PP-GlcNAc), farnesyl-PP-GlcNAc ((ωEE)-PP-GlcNAc), neryl-PP-GlcNAc ((ωZ)-PP-GlcNAc), geranyl-PP-GlcNAc ((ωE)-PP-GlcNAc), and farnesyl-PP-chitobiose ((ωEE)-PP-GlcNAc-1,4-β-GlcNAc) were isolated as final compounds. Phosphonate LLO analogs nerylneryl-PPC-GlcNAc ((ωZZZ)-PPC-GlcNAc) and nerylneryl-PPC(OH)-GlcNAc ((ωZZZ)-PPC(OH)-GlcNAc) were obtained using previously described procedures with modifications 28, 29 . The synthesis required ten and eight steps, respectively from GlcNAc, where the hydroxyl-phosphonate analog was an intermediate in the phosphonate synthesis. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity. 
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For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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